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S U M M A R Y
Objectives: The aim of this study was to evaluate the outcome of cefazolin prophylaxis for total knee
arthroplasty (TKA) in a hospital with a high prevalence of methicillin-resistant Staphylococcus aureus
(MRSA) infection.
Methods: Since July 1, 2006, we have applied a ‘care bundle’ to TKA to prevent surgical site infection (SSI)
without using vancomycin as antimicrobial prophylaxis, in accordance with the 1999 Hospital Infection
Control Practices Advisory Committee guidelines. All patients undergoing TKA from July 1, 2006 to
September 30, 2009 were enrolled. We reviewed data on SSI collected prospectively as part of routine
infection control surveillance.
Results: Of 1323 TKAs, an SSI developed in 14 (1.06%) cases, which is comparable to the percentage
obtained in other previous reports. When stratiﬁed by the National Nosocomial Infection Surveillance
risk index, SSI rates were 0.86% (8/926), 1.30% (5/384), and 7.69% (1/13) in risk categories 0, 1, and 2,
respectively. Of 14 SSIs, four (29%) were classiﬁed as superﬁcial incisional, two (14%) as deep incisional,
and eight (57%) as organ-space SSI.
Conclusions: Our data suggest that antimicrobial prophylaxis using only cefazolin can maintain low SSI
rates if other important infection management measures are employed, even where there is a high
prevalence of MRSA infection.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Surgical site infection (SSI) is a devastating complication,
especially after implantation of prosthetic material. Because of the
increasing prevalence of methicillin-resistant Staphylococcus
aureus (MRSA) infections, there is a perceived need to use
vancomycin for surgical antimicrobial prophylaxis in high-risk
procedures (e.g., arthroplasty) and when endemic rates of SSI due
to MRSA are high. However, ‘high rates’ of MRSA infection have not
been deﬁned and many effective measures exist for preventing SSI
other than antimicrobial prophylaxis.1
MRSA accounts for over 60% of S. aureus nosocomial isolates in
Korea, including in our institution – a tertiary care, university-
afﬁliated 900-bed hospital.2,3 Since 2006 we have applied a ‘care§ This study was presented in part at the 48th Annual Meeting of the Infectious
Diseases Society of America, Vancouver, 2010 (abstract number 380).
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doi:10.1016/j.ijid.2011.09.009bundle’ to total knee arthroplasty (TKA) in order to prevent SSI
without using vancomycin as antimicrobial prophylaxis, in
accordance with the 1999 Hospital Infection Control Practices
Advisory Committee guidelines.4 In this study we evaluated the
outcome of cefazolin prophylaxis for TKA and analyzed the risk
factors for SSI in a hospital with a high endemic rate of MRSA
infection.
2. Methods
2.1. Study setting and patients
Since July 1, 2006, we have applied a ‘care bundle’ to TKA to
prevent SSI at Seoul National University Bundang Hospital, an
academic tertiary care medical center. The care bundle consists of:
(1) the use of an appropriate antiseptic agent for surgical scrub and
skin preparation: aqueous solutions of 10% povidone–iodine and
2% chlorhexidine–alcohol are both considered appropriate; we
used an aqueous solution of 10% povidone–iodine (Povidin, Sungses. Published by Elsevier Ltd. All rights reserved.
Table 1
Surgical site infection rates after total knee arthroplasty, according to National Nosocomial Infection Surveillance risk index category
NNIS risk index category No. of operations No. of SSI SSI ratea (95% CI) KONISb (2008) NHSNc (2009)
0 926 8 0.86 (0.41–1.73) 0.93 0.58
1 384 5 1.30 (0.47–3.10) 1.65 0.99
2, 3 13 1 7.69 (0.01–35.42) 0 1.60
Total 1323 14 1.06 (0.61–1.79) 1.10 NA
SSI, surgical site infection; NNIS, National Nosocomial Infection Surveillance; CI, conﬁdence interval; NA, not available.
a SSI rates are number of SSI cases per 100 operations; 95% conﬁdence intervals were calculated by the modiﬁed Wald method.
b Korean Nosocomial Infections Surveillance System.7
c National Healthcare Safety Network.8
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antimicrobial prophylaxis: timing (1 h before incision), choice
(cefazolin), and duration of therapy (24 h after the procedure);
(3) the following operating room characteristics: enough ventila-
tion (15 times/h) using a HEPA ﬁlter, laminar air ﬂow, and trafﬁc
control; and (4) reporting of compliance with the care to the
attending surgeon every 3 months.
We performed a retrospective cohort study among patients
undergoing TKA, from the initiation of the care bundle to
September 30, 2009. We included all patients undergoing TKA
during that period. These patients were identiﬁed using a surgical
information recording system that routinely captures data on all
surgical cases in both inpatient and outpatient settings in a
prospective manner. We included only the type I surgical wound
classiﬁcation in our analysis; elective TKA is not applicable to
patients with type II wound classiﬁcations.
2.2. Outcome assessment and patient follow-up
The primary outcome was development of any SSI within a year
of surgery. All patients who underwent TKA were registered in the
surgical information recording system. During admission, the
surgical site was examined daily by the attending surgeon and the
clinical information was recorded on a standardized record form.
After discharge, patients were followed up in the outpatient clinic
at 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after surgery,
as scheduled. Surgical site examinations were mainly performed
by the attending surgeon, or if necessary by an infectious disease
specialist. Clinical information (including the surgeon’s description
of the wound, diagnosis, and antibiotic prescriptions, etc.) was
rechecked by an independent infection control practitioner in a
prospective manner. If a patient failed to return for clinical follow-
up, an infection control practitioner contacted the patient by
telephone and asked him/her to complete a standardized form.
During the follow-up period, patients suspected of having an SSI
were identiﬁed by the surgeon or infection control practitioner
using the criteria for SSI of the US Centers for Disease Control and
Prevention (CDC).4,5 Compliance with the care bundle and the
follow-up rate were reported to the attending surgeon every 3
months. As a result, the 1-year follow-up rate was nearly 100%
(99.6%, 1318/1323).
2.3. Statistical analyses
SSI rates were calculated according to the recommendations of
the CDC.4,5 Rates were stratiﬁed by the National Nosocomial
Infection Surveillance (NNIS) risk index, categories 0–2. No
patients were in NNIS category 3 because only type I wounds
were included.6 Differences between patients with SSI and without
SSI were evaluated using the Chi-square test for categorical
variables and the t-test for continuous variables. Univariate logistic
regression was used to assess the association of selected variables
with SSI. All analyses were performed using SPSS software version
17.0 (SPSS Inc, Chicago, IL, USA).3. Results
3.1. Rates and characteristics of surgical site infection
From July 1, 2006 to September 30, 2009, 1323 TKAs were
performed. SSIs occurred in 14 (1.06%) cases, including eight
(0.60%) cases with prosthetic joint infection. When stratiﬁed by the
NNIS risk index, SSI rates were 0.86% (8/926), 1.30% (5/384), and
7.69% (1/13) in risk categories 0, 1, and 2, respectively (Table 1).
Of the 14 procedures that resulted in diagnoses of infections,
four (29%) resulted in SSIs that were classiﬁed as superﬁcial
incisional, two (14%) as deep incisional, and eight (57%) as organ-
space SSI. Most (11/14, 79%) of the SSIs were early-onset infections
(developing within 3 months of surgery).
In all of the cases with SSI, cefazolin was used as antimicrobial
prophylaxis, given less than an hour before incision and
discontinued within 24 h. Pathogens were identiﬁed in eight
(57%) cases: four (50%) methicillin-sensitive S. aureus (MSSA), two
(25%) MRSA, and two (25%) methicillin-resistant coagulase-
negative staphylococci.
Cases with superﬁcial incisional SSIs were treated with simple
dressings or superﬁcial wound revision, and short-term (2
weeks) oral antibiotics. Cases with deep incisional and organ-space
SSIs received open or arthroscopic debridement with retention of
the prosthesis, followed by a long course (at least 3 months) of
intravenous antibiotics with or without subsequent oral agents. All
14 patients with SSI recovered from their infection without
removal of the prosthesis, and there were no cases of relapse
within at least 1 year of treatment.
3.2. Compliance with the care bundle
The preoperative antiseptic agents used in the surgical scrub
and skin preparations were appropriate in all cases. In addition, all
TKAs were performed in the same operating theatre with adequate
ventilation (15 times/h) using HEPA ﬁlters, laminar air ﬂow, and
trafﬁc control. In 98.7% (1306/1323) of the procedures, a
prophylactic antimicrobial agent was administered within 1 h
before incision. Cefazolin was used in 99.4% (1315/1323) of the
cases and an antibiotic was used within 24 h of the procedure in
95.2% (1260/1323) of all the TKAs.
3.3. Risk factors for surgical site infection
The results of univariate analysis of the risk factors associated
with SSI are presented in Table 2. No statistically signiﬁcant risk
factor for SSI was identiﬁed except for preoperative infection
remote from the surgical site.
4. Discussion
In the present study the overall SSI rate after TKA was 1.06%.
This is similar to the SSI rate after surgery in the 2008 Korean
Nosocomial Infection Surveillance (KONIS) report, and higher than
Table 2
Univariate analysis: association of selected risk factors with surgical site infection following total knee arthroplasty
Factors Patients Univariate OR (95% CI)
With SSI
(n = 14)
Without SSI
(n = 1309)
Intrinsic, patient-related (preoperative)
Age, >65 years 11 (79) 954 (73) 1.36 (0.38–4.92)
Gender, male 1 (7) 99 (8) 0.94 (0.12–7.26)
Preoperative hospital stay, 3 days 4 (29) 281 (21) 1.87 (0.56–6.28)
ASA score, 3 2 (14) 78 (6) 2.63 (0.58–11.96)
Diabetes 5 (36) 309 (24) 1.82 (0.61–5.47)
Obesity (BMI 25 kg/m2) 12 (86) 929 (71) 2.45 (0.55–11.02)
Smoking 0 32 (2) -
Immunosuppressive medication 0 17 (1) -
Extrinsic, procedure-related (perioperative)
Preoperative infection at another site 1 (7) 5 (0.4) 20.06 (2.19–183.87)
Operative characteristics
General anesthesia 2 (14) 74 (6) 2.78 (0.61–12.66)
Duration of surgery >75th percentile 5 (36) 325 (25) 1.68 (0.56–5.06)
Repeated knee surgery 1 (7) 44 (3) 2.21 (0.28–17.28)
Antimicrobial prophylaxis
Timing of administration of 1st dose 60 min before incision 14 (100) 1292 (99) 0.39 (0.02–6.85)
Choice, cefazolin 14 (100) 1301 (99) 0.19 (0.01–3.44)
Duration of therapy, 24 h 12 (86) 1248 (95) 0.29 (0.06–1.34)
Use of antibiotic-impregnated cement 7 (50) 713 (54) 0.84 (0.29–2.40)
Operating room characteristics
Laminar ﬂow 14 (100) 1309 (100) -
HEPA ﬁlter in operation 14 (100) 1309 (100) -
Ventilation, air exchange 15 times/h 14 (100) 1309 (100) -
SSI, surgical site infection; OR, odds ratio; CI, conﬁdence interval; ASA, American Society of Anesthesiologists; BMI, body mass index; HEPA, high-efﬁciency particulate air.
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report .7,8 However, active surveillance in this study mainly
consisted of post-discharge surveillance by surgeon examination,
and was carried out for all patients who received a TKA. Moreover
both the microbiological ﬁndings and the clinical information
(including surgeon examination of the wound, diagnosis, and
antibiotic prescription) were rechecked by an independent
infection control practitioner in a prospective manner. Bolon et
al.,9 showed that SSI rates were nearly doubled by active
surveillance based on electronic data including diagnosis, pre-
scription, etc. compared to routine surveillance by microbiological
results alone. Also, as indicated by Huotari and Lyytikainen,10 post-
discharge surveillance greatly impacts on the rate of SSI detected
after orthopedic surgery. Therefore we are unlikely to have missed
any case with SSI, and the SSI rate obtained was either similar to or
lower than those obtained in the 2009 NHSN and 2008 KONIS and
other reports from various countries.7,8,10–12
Recently, as infections due to MRSA have increased, the opinion
has emerged that vancomycin should be used as antimicrobial
prophylaxis in special circumstances.4 However, there is contro-
versy regarding in which situations vancomycin should be used.
There is no consensus about what constitutes ‘high prevalence’ of
methicillin resistance, and there have been few prospective
randomized controlled studies comparing glycopeptides ( beta-
lactam) and beta-lactam antimicrobials as antimicrobial prophylaxis.
Potential adverse effects of the use of vancomycin as antimicrobial
prophylaxis (emergence of resistance, drug toxicity, high cost, and so
forth) should be considered.
Other than making the appropriate choice of antimicrobial
prophylaxis, many important measures can be taken to prevent
SSI, such as appropriate skin preparation, adequate use of
antimicrobial prophylaxis with regard to indication, timing, and
duration of therapy, and adequate ventilation with a HEPA ﬁlter,
laminar air ﬂow, and trafﬁc control in the operating room.1 In view
of this we thought it was more important to abide by infection
management guidelines before using vancomycin, which remains
controversial as antimicrobial prophylaxis. We applied a carebundle to TKA, and compliance was regularly reported to the
attending surgical team. As a result, compliance was over 95% for
all items and we were able to achieve a low SSI rate without using
vancomycin.
This study has a few limitations. First, it was not a prospective
comparative study and so has the disadvantage that we could not
directly compare the effects of vancomycin and cefazolin. Second,
all 14 cases with SSI in our study were completely compliant with
the care bundle and in four (50%) of the eight patients for whom
the cause of infection was identiﬁed, it was due to methicillin-
resistant staphylococci. Hence, the care bundle alone does not
guarantee the lowest SSI rates. Therefore, the use of vancomycin
selectively in certain patients has the potential to reduce SSI, and
further research on this is called for. Third, we used an aqueous
solution of 10% povidone–iodine as antiseptic agent, in accor-
dance with the 1999 Hospital Infection Control Practices Advisory
Committee guidelines.4 However, recent work has demonstrated
signiﬁcant reductions of SSI after clean-contaminated surgery,
and of bloodstream infections after vascular catheter insertion,
when a chlorhexidine-based agent was used for antisepsis.13,14
Although the effect of chlorhexidine-based antisepsis has not
been carefully compared with that of povidone–iodine in clean
surgery (including in arthroplasty), antisepsis with chlorhexi-
dine–alcohol could result in a signiﬁcant clinical beneﬁt. Lastly,
since infection due to community-associated MRSA (CA-MRSA)
is rare in Korea,2 the SSI rate after surgery in regions in which CA-
MRSA is prevalent may be different from that obtained in this
study.
Nevertheless, our data suggest that even where there is a high
prevalence and high incidence of MRSA infection, antimicrobial
prophylaxis in TKA using only cefazolin can maintain low SSI rates
after surgery if other important infection management measures
are employed.
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